In one paragraphArticle in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Thabatta L S A Rosa *Laboratório de Microbiologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.ORCID 0000-0002-4866-8021 Maria Angela M Marques *Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-4680-2653 Daniele F F BertoluciDivisão de Pesquisa e Ensino, Instituto Lauro de Souza Lima, Bauru, State of São Paulo, Brazil.ORCID 0000-0001-6389-9576 Fabricio da M R CostaDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-6757-6587 Linda A FischbacherDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Mariana de Andrea HackerLaboratório de Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.
Ramanuj LahiriNational Hansen's Disease Programs, Laboratory Research Branch, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.ORCID 0000-0001-5922-8307 Márcia Bêrredo-PinhoLaboratório de Microbiologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.ORCID 0000-0003-3598-1892 Patrícia S RosaDivisão de Pesquisa e Ensino, Instituto Lauro de Souza Lima, Bauru, State of São Paulo, Brazil.ORCID 0000-0002-2745-2854 John T Belisle *Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-2539-2798 Maria Cristina V Pessolani *Laboratório de Microbiologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.ORCID 0000-0003-3064-8759 Funding
The Role of Schwann Cell Lipid Droplets In Neuropathology of LeprosyR01AI141526 · NIAID · COLORADO STATE UNIVERSITY · PI BELISLE, JOHN T, PESSOLANI, MARIA CRISTINA VIDAL · 2019 to 2023
$3.1MEstablishing a Long Island Bioscience HubU01HL127522 · NHLBI · STATE UNIVERSITY NEW YORK STONY BROOK · PI RUBIN, CLINTON T · 2015 to 2017
$3.0MValidating cholesterol-mediated Mycobacterium tuberculosis resistance to oxidative stress as a drug targetR01AI134054 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI SAMPSON, NICOLE S · 2017 to 2021
$2.0MConselho Nacional de Desenvolvimento Científico e Tecnológico 432434/2018-6National Institute of Allergy and Infectious Diseases R01AI134054,R01AI141526NHLBI NIH HHS U01 HL127522NHLBI NIH HHS U01HL127522NIAID NIH HHS R01 AI134054NIAID NIH HHS R01 AI141526
6 · The paper itselfAbstract
Although the current multidrug therapy (MDT) for leprosy is very successful, the long treatment duration and the emergence of antibiotic-resistant strains demand for new alternative drugs. One potential target for drug development against pathogenic mycobacteria is their need to degrade host cholesterol during infection.
Indexed as
Leprostatic AgentsLeprosyMycobacterium lepraeAnimalsDisease Models, AnimalFemaleHumansMiceMicrobial Sensitivity TestsLeprostatic Agents3β-HSD6-azasteroidschemotherapycholestenonecholesterolMycobacterium lepraepharmacokinetics
Identifiers
PMID40422284
PMCPMC12210912
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390